Clinical Trial Update: Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial combining chidamide with duvelisib for relapsed or refractory peripheral T-cell lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Chidamide (chidamide)
• Duvalisibon (duvelisib)

Snippet

Sponsor: The First Affiliated Hospital of Xiamen University | Conditions: Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma | Phase 2 | Status: RECRUITING